PDB42 INCRETIN-THERAPY IN ADDITION TO METFORMIN AND/OR SULFONYLUREA FOR TYPE 2 DIABETES MELLITUS (T2DM)- COSTEFFECTIVENESS OF LIRAGLUTIDE VERSUS EXENATIDE FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72100-3
https://www.valueinhealthjournal.com/article/S1098-3015(11)72100-3/fulltext
Title : PDB42 INCRETIN-THERAPY IN ADDITION TO METFORMIN AND/OR SULFONYLUREA FOR TYPE 2 DIABETES MELLITUS (T2DM)- COSTEFFECTIVENESS OF LIRAGLUTIDE VERSUS EXENATIDE FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72100-3&doi=10.1016/S1098-3015(11)72100-3
First page : A291
Section Title : RESEARCH POSTER ABSTRACTS
Open access? : No
Section Order : 258
Categories :
Tags :
Regions :
ViH Article Tags :